Signals, Powered By EquityPandit
US health regulator has closed out the warning letter, which was issued to a unit of Divis Laboratories in Visakhapatnam, following evaluation of corrective actions taken by the company at plant.
The company in a BSE filing stated, “Divi’s Laboratories has been informed by the USFDA that the agency has completed evaluation of the company’s corrective actions in response to FDA’s warning letter..dated April 13, 2017.”
Further it stated that, it had noted there was an update on regulator’s website, regarding closing of the warning letter.
